Thermo Fisher Scientific One Lambda Pre-Transplant Risk Assessment (PTRA) Assay
Thermo Fisher Scientific has launched the One Lambda Pre-Transplant Risk Assessment (PTRA) assay, a pre-transplant risk assessment assay that helps assess the risk of early acute rejection in kidney transplant recipients. The assay was developed and validated by the CLIA-certified Thermo Fisher One Lambda Laboratories and is used clinically as a laboratory-developed test. According to Thermo Fisher, the PTRA assay utilizes 29 mRNA markers to help stratify patients into high- and low-risk categories for early acute rejection. A recent clinical validation study observed that patients with high PTRA scores were six times more likely to experience early acute rejection than patients with low-risk scores, the company said.
Ansa Biotechnologies Ansa Clonal DNA and Ansa DNA Fragments
Ansa Biotechnologies has launched the Ansa Clonal DNA and Ansa DNA Fragments services for enzymatic DNA synthesis. Both Ansa Clonal DNA and Ansa DNA Fragments can achieve the contiguous synthesis of DNA molecules up to 600 bp, with the former producing sequence-perfect clonal DNA and the latter making sequence-verified linear double-stranded DNA fragments. The company said the turnaround time for Ansa Clonal DNA is within 15 business days while that of Ansa DNA Fragments is within five business days.
Cytek Biosciences SpectroPanel Tool for Cloud Digital Ecosystem
Cytek Biosciences has launched the SpectroPanel tool for its Cytek Cloud digital ecosystem. The new tool is a proprietary algorithm that is designed for use within the company's Full Spectrum Profiling technology and suggests optimized panels in minutes by automating the labor-intensive manual process of assigning fluorochromes to markers, the company said. Cytek Cloud is a suite of integrated, online software tools that streamline flow cytometry workflows by combining all spectral panel design tools in one place and allowing users to prepare experiments remotely, the company noted.
Sengenics i-Ome Cancer
Sengenics, a Boston-based functional proteomics company, has launched its i-Ome Cancer biomarker discovery platform for research use only. The platform facilitates high-throughput screening of autoantibodies by leveraging Sengenics' proprietary KREX technology and a focused library of more than 500 expertly curated proteins that are known to be autoantigenic in cancers, including those frequently mutated in cancer or involved in key cancer signaling pathways, the company said.
For more recently launched products and services, please visit the New Products page on our website.